Physician profile
Daisy Borroto
NPI 1932341104
$1,892.69
in general payments reported to CMS, 2019-2025
20 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $14.12 · 2021: $85.24 · 2022: $273 · 2023: $338 · 2024: $477 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337 · Education: $77.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.05 |
| Education | $77.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $378.20 | 2022-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $288.15 | 2021-2025 | Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $193.44 | 2019-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $179.61 | 2023-2025 | |
| Janssen Biotech, INC. | $171.54 | 2025 | |
| Argenx US, INC. | $121.52 | 2025 | Vyvgart |
| Otsuka America Pharmaceutical, INC. | $118.66 | 2024-2025 | Rexulti |
| Catalyst Pharmaceuticals, INC. | $94.46 | 2023-2024 | Fycompa |
| Amneal Pharmaceuticals LLC | $67.33 | 2019-2025 | Ongentys |
| Eisai INC. | $50.67 | 2022 | |
| Allergan, INC. | $38.27 | 2021 | |
| Supernus Pharmaceuticals, INC. | $29.14 | 2019 | |
| Sumitomo Pharma America, INC. | $28.29 | 2023 | Aptiom |
| Ucb, INC. | $25.27 | 2019 | |
| Acadia Pharmaceuticals INC | $22.06 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.61 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $16.86 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.82 | 2019 | |
| Amgen INC. | $16.23 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.56 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Borroto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.